"Spravato helps people who suffer from chronic depression feel better. In conjunction with another antidepressant, it has shown a high success rate. Parkside offers this service to reduce ...

However, it may cover Spravato, an FDA-approved drug deriving ... DRUGDEX Information System and the American Hospital Formulary Service Drug Information — support them. These authorities ...

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Spravato (esketamine ... “Estimates of the costs of providing the clinical service for esketamine were highly uncertain, as are the costs of repeated courses of the drug,” he added.

Recently, the FDA approved Spravato as a monomer treatment ... Injectables core sales decreased 8% due to lower service revenue in tooling. Injectable component sales were up slightly, led ...

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient’s continued service with the Company ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Injectable component sales grew 10% in 2024, but the growth was offset by lower tooling and service revenues ... heard us talk about our nasal bi-dose system for Johnson & Johnson's Spravato ...

The study, conducted at eight National Health Service (NHS) sites across the UK ... to Johnson & Johnson's data on its blockbuster Spravato drug, an esketamine-based treatment for depression.

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, highlight the growing interest in mental health treatment.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat. The United States Food and Drug Administration (FDA ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...